Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5592340 | 0.88 | MGLL (0.54) | MGLLPOLBENPP2TP53MAPT | |
| SCHEMBL5374821 | 0.86 | MGLL (0.52) | MGLLPOLBENPP2TP53MAPT | |
| SCHEMBL5374818 | 0.86 | MGLL (0.52) | MGLLPOLBENPP2TP53MAPT | |
| SCHEMBL14370629 | 0.85 | MGLL (0.51) | MGLLPOLBENPP2TP53MAPT | |
| SCHEMBL29952213 | 0.84 | MGLL (0.56) | MGLLPOLBENPP2TP53MAPT | |
| SCHEMBL4875564 | 0.84 | MGLL (0.56) | MGLLPOLBENPP2TP53MAPT | |
| SCHEMBL12876566 | 0.84 | MGLL (0.56) | MGLLPOLBENPP2TP53MAPT | |
| SCHEMBL18786518 | 0.83 | MGLL (0.58) | MGLLPOLBENPP2TP53MAPT | |
| SCHEMBL29952692 | 0.82 | MGLL (0.56) | MGLLPOLBENPP2TP53MAPT | |
| SCHEMBL29956794 | 0.82 | MGLL (0.56) | MGLLPOLBENPP2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| CN-113272301-B | Heterocyclic compound, intermediate, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-02-01 | — | — | US | disclosed |
| US-20230114728-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2023-04-13 | — | — | US | disclosed |
| US-20230068538-A1 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2023-03-02 | — | — | US | disclosed |
| CN-111377917-B | Heterocyclic compound, intermediate, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2022-12-06 | — | — | CN | disclosed |
| EP-3889154-A1 | HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2007004032-A1 | OXAZOLIDIONES CONTAINING CYCLOBUTANE AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230068538-A1 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | MGLL 3918/4885POLB 4161/4885ENPP2 1411/4885 |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | P2RX3, P2RX7, P2RX4 | MGLL 3918/4885POLB 4161/4885ENPP2 1411/4885 |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | MGLL 3918/4885POLB 4161/4885ENPP2 1411/4885 |
| US-20230114728-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | MGLL 1986/4885POLB 2001/4885ENPP2 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.